Eli Lilly and Company
Mutant IDH1 inhibitors
Last updated:
Abstract:
The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
30 May 2017
Issue date:
30 Jun 2020